Clopidogrel
NDC Package 52605-082-13

11-digit billing NDC: 52605008213

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Clopidogrel is tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Marketed by Polygen Pharmaceuticals Inc., this product is identified by NDC 52605-082 and is authorized under FDA application ANDA213351.

Identification & Billing

NDC Package Code
52605-082-13
Package Description
30 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
52605008213

Clinical Specifications

Proprietary Name
Clopidogrel
Dosage Form
-
Usage Information
Clopidogrel tablets are indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST -elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel tablets should be administered in conjunction with aspirin.Clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel tablets should be administered in conjunction with aspirin.

Regulatory & Marketing

Labeler Name
Polygen Pharmaceuticals Inc.
FDA Application #
ANDA213351
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-01-2021
End Marketing Date
09-14-2026
Listing Expiration
09-14-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (52605-082). Click a package code to view its specific billing and regulatory data.

1000 TABLET in 1 BOTTLE, DISPENSING

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52605-082-13 identifies a specific commercial package of 30 tablet in 1 bottle of Clopidogrel, labeled by Polygen Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Polygen Pharmaceuticals Inc. on March 01, 2021. The current certification is valid through September 14, 2026.

How is this Polygen Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52605008213. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
52605-082-13
11-Digit CMS (5-4-2)
52605-0082-13

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.